# Safety and Clinical Performance of a Sirolimus-eluting Absorbable Metal Scaffold

Study · id `cardio:ct-nct02916485` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02916485](<https://clinicaltrials.gov/study/NCT02916485>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02916485

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 100 participants.

## Technical summary

Registry record NCT02916485. Allocation not applicable; no masking; primary purpose treatment. Start 2017-06 (anticipated); primary completion 2018-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT02916485, source copy `cardio:ctgov-nct02916485-2017-06-14`, retrieved 2026-10-26)
- Planned start: 2017-06 (anticipated) (ClinicalTrials.gov record NCT02916485, source copy `cardio:ctgov-nct02916485-2017-06-14`, retrieved 2026-10-26)
- Primary completion: 2018-02 (anticipated) (ClinicalTrials.gov record NCT02916485, source copy `cardio:ctgov-nct02916485-2017-06-14`, retrieved 2026-10-26)
- Completion: 2018-09 (anticipated) (ClinicalTrials.gov record NCT02916485, source copy `cardio:ctgov-nct02916485-2017-06-14`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT02916485, source copy `cardio:ctgov-nct02916485-2017-06-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "SUSPENDED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02916485-2017-06-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Clinical Performance of a Sirolimus-eluting Absorbable Metal Scaffold
- Acronym: BIOSOLVE-India
- Condition: Coronary Artery Disease
- Intervention (Device): Bioresorbable scaffold
- Lead sponsor: Biotronik AG
- Lead sponsor class: INDUSTRY
- Collaborator: CBCC-VIBGYOR Research Pvt. Ltd.
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Biotronik AG (`cardio:org-biotronik-ag`)

## Provenance

Content hash: 643ab46d5680097e9b50fa5c35bf291beb8f819d4f670c2a2aaa0054a17f2d0c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
